Search clinical trials for: Insulin Aspart

Total 8130 results

Novo Nordisk A/S

Completed

Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin

Diabetes | Type 2 Diabetes Mellitus

Taiwan, Turkey, India, Algeria, Hong Kong, China, Ukraine
Novo Nordisk A/S

Completed

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes (onset®7)

Diabetes | Diabetes Mellitus, Type 1

Germany, United States, India, Israel, Italy, Russian Federation, Japan, Finland, Serbia, Turkey, Bulgaria, Estonia, Czechia, Lithuania, Ukraine, Poland, Latvia, Puerto Rico
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

Austria
Novo Nordisk A/S

Completed

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes (BOOST)

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

A Research Study of How Faster-acting Insulin Aspart Moves Into, Through, and Out of the Body and How it Works in the Body When Given Through an Insulin Pump to People With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Eli Lilly and Company

Completed

Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use

Diabetes Mellitus, Type 1

United States
Novo Nordisk A/S

Completed

A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

Poland, Croatia, Germany, Turkey, Slovakia, Bulgaria, Romania, Algeria, Czechia, Ukraine
Halozyme Therapeutics

Completed

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

United States
Halozyme Therapeutics

Completed

Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase

Type 1 Diabetes Mellitus

United States
Emory University
Boston Medical Center; Rush University; University of Denver

Completed

Linagliptin Inpatient Trial

Type 2 Diabetes

United States
Novo Nordisk A/S

Completed

A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients

Diabetes Mellitus, Type 2 | Diabetes

India, Serbia, Bulgaria, Australia, Korea, Republic of, Thailand, Turkey, United Arab Emirates, Hungary
University of Palermo

Completed

Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables

Diabetes Mellitus

Italy
Novo Nordisk A/S

Completed

Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes (onset® 2)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, India, Israel, Russian Federation, Slovakia, Canada, Serbia, United Kingdom, Puerto Rico
University of Texas Southwestern Medical Center
Novo Nordisk A/S

Withdrawn

Aggressive Versus Conservative Blood Glucose Control in Hospitalized Type 2 Diabetic Patients Using Detemir and Aspart Insulin (RASCIN)

Type 2 Diabetes

United States
Merck Sharp & Dohme LLC

Completed

A Three-part Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Healthy Participants (Part I) and Participants With Type 1 Diabetes Mellitus (Parts II and III) (MK-2640-001)

Type 1 Diabetes Mellitus
University of Texas Southwestern Medical Center

Withdrawn

Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes

Type 1 Diabetes

United States
Novo Nordisk A/S

Completed

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes (SWITCH 1)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, Puerto Rico
Novo Nordisk A/S

Completed

A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

Japan, Malaysia, Taiwan, Korea, Republic of, Hong Kong
Novo Nordisk A/S

Completed

Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

India, Denmark, Sweden, Malaysia, Poland, Turkey, Finland, Australia, Thailand, Taiwan
Novo Nordisk A/S

Completed

Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacodynamic Properties of NN1218 in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Huazhong University of Science and Technology

Completed

Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM

Type 2 Diabetes Mellitus

China
Xijing Hospital
Xi'an Central Hospital; First Affiliated Hospital Xi'an Jiaotong University; Shaanxi... and other collaborators

Completed

Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes

Type 2 Diabetes Mellitus

China
Halozyme Therapeutics

Completed

CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)

Type 1 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan

Diabetes Mellitus, Type 2 | Diabetes

United Arab Emirates, Malaysia, India, South Africa, Algeria, Lebanon
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005)

Type 1 Diabetes Mellitus
Novo Nordisk A/S

Terminated

Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma (iINHALE 9)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1 | Asthma

United States, Slovakia, India, Malaysia, Australia, Former Serbia and Montenegro
Novo Nordisk A/S

Terminated

Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United States, Canada
Novo Nordisk A/S

Completed

A Non-interventional Study of Ability and Willingness to Pay for BIAsp 30 in a Real World Population With Type 2 Diabetes Mellitus (T2DM)

Diabetes Mellitus, Type 2 | Diabetes

India
Mackay Memorial Hospital

Completed

Comparison of Premixed Insulin With Basal-plus Insulin in Type 2 Diabetes Patients (COMPAR)

Diabetes

Taiwan
Albert Einstein College of Medicine
Medtronic

Completed

Randomized Trial Comparing Sitagliptin to Placebo in Closed Loop

Diabetes Mellitus, Type 1

United States
Montefiore Medical Center
Amylin Pharmaceuticals, LLC.

Completed

Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

United States
Tehran University of Medical Sciences

Completed

Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease

Non-alcoholic Fatty Liver Disease

Iran, Islamic Republic of
Tehran University of Medical Sciences

Completed

Helicobacter Pylori Eradication in Non-diabetic Non-alcoholic Steatohepatitis

Non-alcoholic Fatty Liver Disease

Iran, Islamic Republic of
Emory University

Completed

Sitagliptin in Non-Diabetic Patients Undergoing General Surgery

Hyperglycemia

United States
University Hospital, Montpellier

Completed

Comparison of an Artificial Pancreas Versus Threshold Low Glucose Suspend in Type 1 Diabetic Children (SHAN)

Type 1 Diabetes

France
Institut de Recherches Cliniques de Montreal

Withdrawn

Comparison of the Efficacy of Rapid-acting Aspart and Faster Acting Aspart Within the Context of Single-hormone Closed-loop Strategy at Regulating Postprandial Glucose Levels

Type 1 Diabetes Mellitus
Novo Nordisk A/S

Completed

A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin

Diabetes Mellitus, Type 2 | Diabetes

United States, France, Austria, Norway, Algeria
Novo Nordisk A/S

Completed

Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine (BOOST®)

Diabetes Mellitus, Type 2 | Diabetes

United States, Malaysia, Germany, Algeria, Turkey
Novo Nordisk A/S

Completed

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

United States, Israel, Slovakia, Spain, France, Hungary, Mexico, Russian Federation, Turkey, Czechia, Greece, Argentina
Novo Nordisk A/S

Completed

Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec/Insulin Aspart) in Patients With Diabetes Mellitus in Routine Clinical Practice in India

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

India
Novo Nordisk A/S

Completed

A Randomised Proof-of-Principle Trial Investigating Pharmacodynamics, Pharmacokinetics, and Safety of NNC0143-0406 in Subjects With Type 1 Diabetes Mellitus

Diabetes | Diabetes Mellitus, Type 1

Austria
Emory University

Completed

Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery (SITACABG NonDM)

Coronary Artery Disease

United States
Medical University of Warsaw

Completed

Normal Versus Dual Wave Insulin Bolus for High-protein Food

Type 1 Diabetes

Poland
Kathleen Dungan
Novo Nordisk A/S

Completed

Prandial Insulin Dosing in Hospitalized Patients (ICHO)

Diabetes | Admitting Hospital | Non-critically Ill

United States
Novo Nordisk A/S

Completed

Observational Study of Safety and Effectiveness of NovoMix® 30 for the Treatment of Diabetes (IMPROVE™)

Diabetes Mellitus, Type 2 | Diabetes

Saudi Arabia, China, India, Iran, Islamic Republic of, Korea, Republic of, Russian Federation, Poland, Japan, Italy, Canada, Greece
Emory University

Completed

Point-of-Care Glucose Testing and Insulin Supplementation (POC)

Diabetes

United States
Adocia

Completed

A Trial to Evaluate the Pharmacokinetic and Pharmacodynamic Properties of BioChaperone® Insulin Lispro, Fiasp® and NovoRapid® Delivered by an Insulin Pump

Type1 Diabetes Mellitus

Germany

3

Subscribe